PL1896507T3 - Przeciwciała monoklonalne anty-CD71 i ich zastosowanie do leczenia złośliwych komórek nowotworowych - Google Patents
Przeciwciała monoklonalne anty-CD71 i ich zastosowanie do leczenia złośliwych komórek nowotworowychInfo
- Publication number
- PL1896507T3 PL1896507T3 PL06795343T PL06795343T PL1896507T3 PL 1896507 T3 PL1896507 T3 PL 1896507T3 PL 06795343 T PL06795343 T PL 06795343T PL 06795343 T PL06795343 T PL 06795343T PL 1896507 T3 PL1896507 T3 PL 1896507T3
- Authority
- PL
- Poland
- Prior art keywords
- monoclonal antibodies
- malignant tumour
- tumour cells
- treating malignant
- cells
- Prior art date
Links
- 201000011510 cancer Diseases 0.000 title abstract 2
- 210000004881 tumor cell Anatomy 0.000 title abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 201000005969 Uveal melanoma Diseases 0.000 abstract 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 abstract 1
- 239000012636 effector Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000007246 mechanism Effects 0.000 abstract 1
- 230000001394 metastastic effect Effects 0.000 abstract 1
- 206010061289 metastatic neoplasm Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/154,262 US7736647B2 (en) | 2005-06-15 | 2005-06-15 | Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells |
PCT/IB2006/002331 WO2007000671A2 (en) | 2005-06-15 | 2006-06-14 | Anti-cd71 monoclonal antibodies and uses thereof for treating malignant tumour cells |
EP06795343A EP1896507B1 (en) | 2005-06-15 | 2006-06-14 | Anti-cd71 monoclonal antibodies and uses thereof for treating malignant tumour cells |
Publications (1)
Publication Number | Publication Date |
---|---|
PL1896507T3 true PL1896507T3 (pl) | 2010-08-31 |
Family
ID=37573538
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL06795343T PL1896507T3 (pl) | 2005-06-15 | 2006-06-14 | Przeciwciała monoklonalne anty-CD71 i ich zastosowanie do leczenia złośliwych komórek nowotworowych |
Country Status (10)
Country | Link |
---|---|
US (2) | US7736647B2 (pl) |
EP (1) | EP1896507B1 (pl) |
JP (1) | JP5185815B2 (pl) |
AT (1) | ATE459653T1 (pl) |
CA (1) | CA2612486A1 (pl) |
DE (1) | DE602006012672D1 (pl) |
DK (1) | DK1896507T3 (pl) |
ES (1) | ES2341625T3 (pl) |
PL (1) | PL1896507T3 (pl) |
WO (1) | WO2007000671A2 (pl) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2011003601A (es) * | 2008-10-23 | 2011-04-27 | Hoffmann La Roche | Determinacion de acido nucleico que codifica inmunoglobulina. |
CN104710504B (zh) | 2009-07-22 | 2019-09-13 | 锕医药股份有限公司 | 用于制备放射性免疫缀合物的方法 |
WO2011130164A2 (en) * | 2010-04-13 | 2011-10-20 | The Regents Of The University Of California | Unconjugated anti-tfr antibodies and compositions thereof for the treatment of cancer |
FR2959416B1 (fr) * | 2010-05-03 | 2012-06-22 | Monoclonal Antibodies Therapeutics Mat Biopharma | Utilisation d'anticorps anti-cd71 pour la preparation d'un medicament |
DK2646470T3 (en) | 2010-11-30 | 2017-05-08 | Hoffmann La Roche | ANTI-TRANSFERRIN RECEPTOR ANTIBODIES WITH LOW AFFINITY AND ITS USE FOR TRANSPORTING THERAPEUTIC SCFV OVER THE BLOOD-BRAIN BARRIER |
US9623117B2 (en) * | 2011-04-04 | 2017-04-18 | Wisconsin Alumni Research Foundation | Method for selective targeting and entry of bacterial toxins to cells |
JP2014518615A (ja) * | 2011-04-22 | 2014-08-07 | エマージェント プロダクト デベロップメント シアトル, エルエルシー | 前立腺特異的膜抗原結合タンパク質および関連組成物ならびに方法 |
US9696312B2 (en) | 2011-09-02 | 2017-07-04 | The Trustees Of Columbia University In The City Of New York | Diagnosis and treatment of cancer expressing ILT3 or ILT3 ligand |
EA201700111A1 (ru) | 2011-10-28 | 2018-02-28 | Тева Фармасьютикал Австралия Пти Лтд | Полипептидные конструкции и их применение |
ES2992753T3 (en) | 2012-08-24 | 2024-12-17 | Univ California | Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis |
BR112017023868A2 (pt) | 2015-05-04 | 2018-07-24 | Cytomx Therapeutics Inc | anticorpos anti-itga3, anticorpos anti-itga3 ativáveis, e métodos de uso dos mesmos |
US10179817B2 (en) | 2015-05-04 | 2019-01-15 | Cytomx Therapeutics, Inc. | Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereof |
EP3325006A4 (en) | 2015-07-17 | 2019-03-06 | The Trustees of Columbia University in the City of New York | METHOD FOR TREATING CD166-EXPRESSIVE CANCER |
EA201890613A1 (ru) | 2015-09-21 | 2018-10-31 | Аптево Рисёрч Энд Девелопмент Ллс | Полипептиды, связывающие cd3 |
UA125898C2 (uk) | 2016-03-04 | 2022-07-06 | Джн Байосайєнсіз, Ллк | Антитіла до tigit |
MA45328A (fr) * | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Compositions acide nucléique-polypeptide et utilisations de celles-ci |
EP3473270B1 (en) | 2016-06-20 | 2022-11-30 | Genahead Bio, Inc. | Antibody-drug conjugate |
IL299099B1 (en) | 2016-06-27 | 2025-03-01 | Univ California | Combinations of cancer treatments |
US10611823B2 (en) | 2016-12-14 | 2020-04-07 | Hanssen Biotech, Inc | CD137 binding fibronectin type III domains |
CN110225770B (zh) | 2016-12-14 | 2022-04-26 | 杨森生物科技公司 | 结合cd8a的纤连蛋白iii型结构域 |
EP3554535A4 (en) | 2016-12-14 | 2020-10-21 | Janssen Biotech, Inc. | PD-L1 BINDING FIBRONECTIN TYPE III DOMAINS |
JP7573966B2 (ja) | 2017-01-06 | 2024-10-28 | アビディティー バイオサイエンシーズ,インク. | エクソンスキッピングを誘導する核酸ポリペプチド組成物および方法 |
US20180303952A1 (en) | 2017-03-09 | 2018-10-25 | Cytomx Therapeutics, Inc. | Cd147 antibodies, activatable cd147 antibodies, and methods of making and use thereof |
GB201711809D0 (en) | 2017-07-21 | 2017-09-06 | Governors Of The Univ Of Alberta | Antisense oligonucleotide |
WO2019173771A1 (en) | 2018-03-09 | 2019-09-12 | Cytomx Therapeutics, Inc. | Activatable cd147 antibodies and methods of making and use thereof |
KR102258014B1 (ko) * | 2019-05-15 | 2021-05-27 | 강원대학교 산학협력단 | 암 줄기세포 세포막 단백질에 특이적인 항체 및 그 응용 |
KR102258015B1 (ko) * | 2019-05-15 | 2021-05-27 | 강원대학교 산학협력단 | 암 줄기세포 세포막 단백질에 특이적인 항체 및 그 응용 |
CN114127117B (zh) * | 2019-07-19 | 2024-03-15 | 上海药明合联生物技术有限公司 | 用于偶联的多肽复合物及其应用 |
JP2022548310A (ja) | 2019-09-23 | 2022-11-17 | シートムエックス セラピューティクス,インコーポレイテッド | 抗cd47抗体、活性化可能抗cd47抗体、およびその使用方法 |
WO2021076574A2 (en) | 2019-10-14 | 2021-04-22 | Aro Biotherapeutics Company | Fn3 domain-sirna conjugates and uses thereof |
EP4045061A4 (en) | 2019-10-14 | 2024-04-17 | ARO Biotherapeutics Company | FIBRONECTIN TYPE III DOMAINS BINDING TO CD137 |
IL298111A (en) | 2020-06-02 | 2023-01-01 | Arcus Biosciences Inc | Antibodies to tigit |
EP4323409A4 (en) | 2021-04-14 | 2025-04-16 | Aro Biotherapeutics Company | CD71-BINDING FIBRONECTIN TYPE III DOMAINS |
CA3215367A1 (en) | 2021-04-14 | 2022-10-20 | Swapnil Kulkarni | Fn3 domain-sirna conjugates and uses thereof |
EP4396231A1 (en) | 2021-09-01 | 2024-07-10 | Biogen MA Inc. | Anti-transferrin receptor antibodies and uses thereof |
WO2025024334A1 (en) | 2023-07-21 | 2025-01-30 | Marrow Therapeutics, Inc. | Hematopoietic cell targeting conjugates and related methods |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5308626A (en) | 1985-06-28 | 1994-05-03 | Toni N. Mariani | Lymphokine activated effector cells for antibody-dependent cellular cytotoxicity (ADCC) treatment of cancer and other diseases |
CA2081368A1 (en) | 1990-03-27 | 1991-09-28 | Ian S. Trowbridge | Method for inhibiting cell growth and compositions useful therefor |
US5762932A (en) * | 1990-04-26 | 1998-06-09 | University Of Iowa Research Foundation | Combined treatment of iron depletion and IgG antibody |
US6107090A (en) * | 1996-05-06 | 2000-08-22 | Cornell Research Foundation, Inc. | Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains |
KR101295139B1 (ko) | 2004-06-07 | 2013-08-12 | 레이븐 바이오테크놀로지스, 인코퍼레이티드 | 트랜스페린 리셉터 항체 |
-
2005
- 2005-06-15 US US11/154,262 patent/US7736647B2/en not_active Expired - Fee Related
-
2006
- 2006-06-14 WO PCT/IB2006/002331 patent/WO2007000671A2/en active Application Filing
- 2006-06-14 EP EP06795343A patent/EP1896507B1/en not_active Not-in-force
- 2006-06-14 AT AT06795343T patent/ATE459653T1/de active
- 2006-06-14 JP JP2008516448A patent/JP5185815B2/ja not_active Expired - Fee Related
- 2006-06-14 ES ES06795343T patent/ES2341625T3/es active Active
- 2006-06-14 DE DE602006012672T patent/DE602006012672D1/de active Active
- 2006-06-14 CA CA002612486A patent/CA2612486A1/en not_active Abandoned
- 2006-06-14 DK DK06795343.0T patent/DK1896507T3/da active
- 2006-06-14 PL PL06795343T patent/PL1896507T3/pl unknown
- 2006-06-14 US US11/922,025 patent/US8409573B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP5185815B2 (ja) | 2013-04-17 |
DK1896507T3 (da) | 2010-06-07 |
JP2009509497A (ja) | 2009-03-12 |
US20110311544A1 (en) | 2011-12-22 |
EP1896507A2 (en) | 2008-03-12 |
US20060286030A1 (en) | 2006-12-21 |
US7736647B2 (en) | 2010-06-15 |
DE602006012672D1 (de) | 2010-04-15 |
ATE459653T1 (de) | 2010-03-15 |
US8409573B2 (en) | 2013-04-02 |
WO2007000671A3 (en) | 2007-04-26 |
CA2612486A1 (en) | 2007-01-04 |
EP1896507B1 (en) | 2010-03-03 |
ES2341625T3 (es) | 2010-06-23 |
WO2007000671A2 (en) | 2007-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL1896507T3 (pl) | Przeciwciała monoklonalne anty-CD71 i ich zastosowanie do leczenia złośliwych komórek nowotworowych | |
SG171690A1 (en) | Treatment of protein degradation disorders | |
TW200740844A (en) | Novel MAdCAM antibodies | |
NO2017019I1 (no) | Diarylhydantoinforbindelse, farmasøytisk sammensetning og anvendelse derav | |
UA94707C2 (en) | Antigen-binding molecule capable of binding to plgf | |
MX2010005022A (es) | Anticuerpos que unen celulas dendriticas y epiteliales 205 (dec-205) humanas. | |
UA101478C2 (ru) | Соединения, полезные как ингибиторы raf-киназы | |
WO2006029219A3 (en) | Human monoclonal anti-ctla4 antibodies in cancer treatment | |
MX2020011789A (es) | Anticuerpos monoclonales contra claudina-18 para el tratamiento de cancer. | |
TW200738748A (en) | Human monoclonal antibody human CD134 (OX40) and methods of making and using same | |
MX2009005455A (es) | (r)-n-estereoisomeros de analogos de 7,8-saturados-4,5 epoxi-morfinano. | |
MX2011006959A (es) | Compuestos substituidos de 5,6-dihidro-6-fenilbenzo [f] isoquinolina-2-amina. | |
TNSN08370A1 (en) | Tetrahydropyridothienopyrimidine compounds and methods of use thereof | |
UA99602C2 (ru) | Антитело, специфически связывающееся с jam-a, способное ингибировать пролиферацию опухолевых клеток | |
NZ579478A (en) | Epha3 antibodies for the treatment of solid tumors | |
WO2004058705A3 (en) | Inhibitors of the binding of chemokines i-tac or sdf-1 to the ccxckr2 receptor | |
TW200738236A (en) | Certain chemical entities, compositions, and methods | |
TW200621260A (en) | Selected fused heterocyclics and uses thereof | |
HK1116198A1 (en) | Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth | |
PL1776103T3 (pl) | Kompleksy rutenu do leczenia raków | |
UA96426C2 (ru) | Выделенное человеческое или гуманизированное антитело, которое специфически связывается с il-13 | |
TW200621270A (en) | Novel use of nanogold for manufacturing medicaments for inhibiting metastasis of malignant tumors and growth of leukemic cells, and pharmaceutical compositions for inhibiting metastasis of malignant tumors and for treating leukemia comprising nanogold | |
UA93875C2 (ru) | Выделенное химерическое или гуманизированное антитело, kotopoe специфически связывается c полипептидом tat10772 (ca125) | |
TW200504026A (en) | N-aryl-heteroaromatic products, compositions containing them and use thereof | |
WO2006125139A3 (en) | Therapeutic uses of kallikreins |